Photo: rawpixel · CC0
Theranos claimed it could run hundreds of laboratory blood tests using only a few drops of blood from a finger prick, on its own compact machines, faster and far cheaper than conventional labs. The promise was to move routine blood testing out of central laboratories and into pharmacies and homes.
The specific promises
The pitch had several parts, and each one was a meaningful claim on its own. Together they described a complete replacement for the existing laboratory model.
| Claim | What it meant in practice |
|---|---|
| A few drops of blood | A finger prick instead of a venous draw with a needle and vials |
| Hundreds of tests | A full diagnostic menu from a single tiny sample |
| Proprietary devices | Compact analyzers branded Edison, run on site rather than in a central lab |
| Lower cost and transparent pricing | Published prices, positioned well below standard lab billing |
| Retail locations | Testing centers inside pharmacy stores, close to where people already shop |
The company was founded in 2003 and spent roughly a decade largely out of public view before the claims became widely publicized.
Why the technical problem was so hard
Blood testing at scale is a solved problem only because laboratories use large, expensive, highly specialized instruments and enough sample volume to work with. A finger prick produces a small capillary sample that can be diluted by tissue fluid and can vary between draws.
Running many separate assays from that one small sample means dividing it further and diluting it, which pushes the measurement toward the edge of what any instrument can detect reliably. Small errors get multiplied by the dilution factor. That is the core reason experts treated the claimed test menu as extraordinary rather than incremental.
How the story came apart
- Reporting by The Wall Street Journal in 2015 raised questions about how many tests the company’s own devices actually performed.
- The company had been running many tests on conventional commercial analyzers rather than its proprietary machines.
- In 2016 the Centers for Medicare and Medicaid Services sanctioned the company’s California laboratory over testing practices.
- The retail pharmacy partnership ended, and previously issued test results were voided.
- The company was dissolved in 2018. Federal fraud prosecutions followed, and the two senior executives were convicted in 2022.
What the case is now used to illustrate
Theranos has become the standard reference point in discussions of health technology claims, and the lessons cited most often are procedural rather than scientific. The company kept its methods confidential, citing trade secrets, which meant its central claims were never published in peer reviewed literature where other scientists could test them.
Its board was heavy with prominent figures from government and business and light on laboratory medicine. And the product was deployed to real patients while the underlying technology was still unproven, which is the part that turned a failed startup into a public health matter. Business schools and journalism programs still teach the case for exactly those reasons.
